Zejula (niraparib) begins blocking DNA repair enzymes in cancer cells shortly after you take it, but there’s no single moment when you or your doctor can confirm it’s “working.” Because Zejula is a maintenance therapy, its job is to keep cancer from coming back or progressing after chemotherapy has already shrunk it. That means its effectiveness is measured over months, not days, and you won’t feel a noticeable change the way you might with a pain reliever or antibiotic.
How Zejula Works at the Cellular Level
Zejula is a PARP inhibitor. PARP enzymes are part of the repair crew inside your cells. When DNA gets damaged, PARP proteins rush to the site and help fix it. Cancer cells rely heavily on this repair pathway, especially if they already have flaws in other repair systems (like BRCA mutations). Zejula blocks PARP-1 and PARP-2 enzymes and traps them on damaged DNA, which prevents cancer cells from patching themselves up. Without functioning repair, those cells accumulate so much damage that they die.
This process starts at the molecular level within hours of your first dose. But individual cancer cells dying off doesn’t translate into something you can see on a scan or measure in a blood test right away. The drug needs weeks to months of continuous daily use to produce a measurable impact on tumor activity.
When You’ll Know It’s Working
Because Zejula is a maintenance treatment, not a tumor-shrinking treatment, the goal isn’t to watch a mass get smaller. Instead, your oncologist is looking for the absence of progression: stable or declining CA-125 levels, clean or unchanged imaging, and no new symptoms. The prescribing information doesn’t specify a fixed schedule for the first follow-up scan, so the timing depends on your oncologist’s judgment, your specific cancer history, and how you’re tolerating the drug. Many oncologists order imaging and bloodwork every two to three months during the first year, though this varies.
In practical terms, if you’ve been on Zejula for several months and your scans remain stable, that is the drug working. The benefit accumulates quietly over time rather than announcing itself with a dramatic improvement.
What Clinical Trials Show About Effectiveness
The clearest picture of Zejula’s timeline comes from the PRIMA trial, which studied it as first-line maintenance therapy after platinum-based chemotherapy. Among patients whose cancers had homologous recombination deficiency (a category that includes BRCA mutations and other DNA repair problems), the median time before cancer progressed was 24.5 months on Zejula compared to 11.2 months on placebo. That’s roughly a year of additional progression-free time.
For the broader group of all enrolled patients regardless of genetic status, Zejula extended median progression-free survival from 8.2 months to 13.8 months. Even among patients whose tumors did not have these specific DNA repair deficiencies, the drug still provided a benefit: 8.4 months versus 5.4 months.
These numbers represent medians, meaning half of patients did better and half did worse. They also illustrate that Zejula’s benefit plays out over many months. You won’t have a meaningful signal of whether the drug is helping until you’ve been on it for a while and have follow-up data to compare against your baseline.
What Happens in the First Few Weeks
While the anticancer effects take time to measure, side effects tend to show up much sooner. The most common early issue is a drop in blood cell counts, particularly platelets. In the PRIMA trial, the median time to onset of significant low platelet counts was about 22 days after starting treatment. Low red blood cells (anemia) and low white blood cells (neutropenia) also tend to appear early and then decrease in frequency over time.
This is why your doctor will check your blood counts weekly for the first month, then monthly for the next 11 months. Blood pressure and heart rate monitoring is also recommended at least weekly for the first two months, since Zejula can raise both. These early check-ins are about managing safety rather than assessing whether the drug is fighting cancer.
If your blood counts drop significantly, your oncologist may pause the medication or reduce your dose. This doesn’t mean the drug isn’t working. Dose adjustments are common and expected with PARP inhibitors.
Who Zejula Is Approved For
Zejula is FDA-approved for two specific situations. The first is maintenance treatment for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer who responded to first-line platinum chemotherapy and whose tumors are HRD-positive, meaning they carry BRCA mutations or other markers of genomic instability. The second is maintenance treatment for adults with germline BRCA-mutated recurrent ovarian cancer who responded to platinum-based chemotherapy.
In both cases, Zejula is taken daily as a continuous therapy. It’s designed to be used after chemotherapy has already done the heavy lifting of reducing the cancer. Your oncologist determines eligibility through a companion diagnostic test that identifies whether your tumor has the right genetic profile to benefit from a PARP inhibitor.
What “Working” Really Means for Maintenance Therapy
If you’re used to chemotherapy, where you can sometimes feel tumors shrinking or see dramatic changes on scans, maintenance therapy can feel frustratingly quiet. Zejula’s success looks like nothing happening: no rising tumor markers, no new spots on imaging, no return of symptoms. Months of uneventful follow-up appointments are the best possible outcome.
The drug is active in your body from the first dose, but its clinical value unfolds over the course of many months. Your oncologist will track your progress through regular bloodwork and imaging, and the longer your cancer remains stable or in remission, the stronger the evidence that Zejula is doing its job.